DBV Technologies’ VIASKIN® Patch Yields 48% Response in Asthmatic Kids; THRIVE Trial Underway
DBVT•VIASKIN® Peanut Patch achieved a 48.3% response rate versus 19.6% placebo in asthmatic children (risk difference 28.8; p<0.0001) and showed similar efficacy in other atopic subgroups. DBV Technologies has launched its THRIVE Phase 2 trial enrolling 250 infants (6–12 months) for three-year therapy to reach ad lib peanut consumption.
1. VITESSE Phase 3 Subgroup Results
The VITESSE study randomized 654 peanut-allergic children aged 4–7 years to VIASKIN® Peanut Patch (n=438) or placebo (n=216). Subgroup prevalence included asthma in 35.8%, additional food allergies in 56.6% and atopic dermatitis in 61.8%. At 12 months, response rates were significantly higher with active treatment versus placebo: asthma 48.3% vs. 19.6% (risk difference 28.8; 95% CI 15.79–41.76), food allergy 46.8% vs. 13.6% (risk difference 33.2; 95% CI 23.50–42.83) and dermatitis 47.2% vs. 13.2% (risk difference 34.0; 95% CI 25.09–42.94).
2. THRIVE Phase 2 Trial Design
DBV Technologies has initiated a single-arm, open-label Phase 2 study enrolling approximately 250 infants aged 6–12 months with confirmed peanut allergy. Participants will receive VIASKIN® Peanut Patch over three years, with the primary endpoint of achieving ad lib peanut consumption. Safety and sustained immunomodulation in this younger cohort will be closely monitored.
3. Next Steps and Potential Impact
Oral presentations of VITESSE subgroup data are scheduled for mid-June, with full publication to follow. Completion of the THRIVE study in three years will inform future immunotherapy protocols and underpin potential regulatory filings, positioning the VIASKIN® Peanut Patch as a proactive, non-invasive peanut allergy treatment option if approved.
